bosutinib
bosutinib: 7 clinical trials tracked.
bosutinib evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about bosutinib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (7)
This is a Global, Multi-center, Open-label Randomized and Registrational Phase 3 Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia
Primary endpoint: MMR rate Part A
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment
Primary endpoint: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Primary endpoint: Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI
A Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
Primary endpoint: Cumulative response rate in partial and complete haematological response (PHR/CHR)
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Primary endpoint: Rate of Molecular Response 4.5 (MR4.5)
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial
Primary endpoint: Objective response rate defined as the number of patients with complete response or partial response
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Primary endpoint: Major Molecular Response (MMR) Rate at 24 Weeks